Inhibition of FGFR4 increases oxaliplatin and 5-fluorouracil sensitivity in Kras wild-type and mutant colorectal cancer cells.
R. C. Turkington
No relevant relationships to disclose
W. L. Allen
No relevant relationships to disclose
L. Stevenson
No relevant relationships to disclose
V. Coyle
No relevant relationships to disclose
P. V. Jithesh
No relevant relationships to disclose
I. Proutski
No relevant relationships to disclose
C. Fenning
No relevant relationships to disclose
G. Stewart
No relevant relationships to disclose
S. Van Schaeybroeck
No relevant relationships to disclose
D. Longley
No relevant relationships to disclose
P. G. Johnston
Employment or Leadership Position - Almac Diagnostics
Consultant or Advisory Role - Chugai Pharma; Roche; Sanofi
Stock Ownership - Almac Diagnostics; Fusion Antibodies
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Roche; Sanofi
Research Funding - Amgen; AstraZeneca